⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
QURE News
uniQure N.V.
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
prnewswire.com
QURE
QURE INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of uniQure N.V. Investors
accessnewswire.com
QURE
Pomerantz LLP Informs Shareholders of Securities Class Action Against uniQure N.V. – QURE
accessnewswire.com
QURE
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
prnewswire.com
QURE
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman
globenewswire.com
QURE
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman
globenewswire.com
QURE
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
globenewswire.com
QURE
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
globenewswire.com
QURE
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
globenewswire.com
QURE
QURE Shareholder Alert: April 13, 2026 Lead Plaintiff Deadline in uniQure N.V. Securities Class Action Lawsuit — The Gross Law Firm
globenewswire.com
QURE